Kazia Therapeutics Limited
- Jurisdiction
Australia - ISIN
AU000000KZA9 (KZA.AX )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
3
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
2
/ 7
Profile
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Read full profile
Stock price
Fundamentals
- Net revenue
€1.39M - Gross margin
100.0% - EBIT
-€21.83M - EBIT margin
-1,570.5% - Net income
-€18.85M - Net margin
-1,356.3%
Statement period: - (published )
Dividends
No dividend payouts